Lazard Asset Management LLC Revance Therapeutics, Inc. Transaction History

Lazard Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $885,484 - $1.94 Million	77,200 New	77,200 $885,000
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $1.58 Million - $3.04 Million	86,155 New	86,155 $2.78 Million
Q2 2022 Aug 09, 2022	SELL	$11.52 - $20.4 $63,175 - $111,873	-5,484 Reduced 33.07%	11,099 $153,000
Q1 2022 May 13, 2022	SELL	$12.36 - $20.31 $104,627 - $171,924	-8,465 Reduced 33.8%	16,583 $323,000
Q4 2021 Feb 09, 2022	BUY	$12.46 - $27.87 $312,098 - $698,087	25,048 New	25,048 $408,000
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $15,261 - $19,660	-592 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$26.8 - $31.84 $291,155 - $345,909	-10,864 Reduced 94.83%	592 $17,000
Q1 2021 May 14, 2021	SELL	$24.03 - $29.97 $112,027 - $139,720	-4,662 Reduced 28.92%	11,456 $320,000
Q4 2020 Feb 11, 2021	BUY	$23.41 - $28.34 $377,322 - $456,784	16,118 New	16,118 $456,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.